Bosutinib
Especificaciones
380843-75-4Número CAS
700-455-1Número CE
4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrileNombre IUPAC
C26H29Cl2N5O3Fórmula química
530.4 g/molPeso molecular
Bosutinib; 380843-75-4; SKI-606; SKI 606; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; SK-606; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; 5018V4AEZ0; CHEBI:39112; DTXSID10861568; 3-Quinolinecarbonitrile, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-; bosutinibum; uglysycpd2; RefChem:58901; DTXCID40207910; L01XE14; 4-Anilinobenzo(g)quinoline-3-carbonitrile; 700-455-1; 943-866-3; 4-Anilino-3-quinolinecarbonitrile; Bosutinib (SKI-606); BOSULIF; SKI606; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib (USAN); Bosutinib [USAN]; MFCD07367846; 4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; BOSUTINIB ISOMER 1; CHEMBL288441; C26H29Cl2N5O3; SKI-606); 4-(2,4-dichloro-5-methoxy-anilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib [USAN:INN]; NCGC00241107-01; UNII-5018V4AEZ0; Bosutinib API; Bosutinib (Standard); Bosutinib,SKI-606; BOSUTINIB [INN]; BOSUTINIB [MI]; BOSUTINIB [VANDF]; PF-5208763; BOSUTINIB [MART.]; EC 700-455-1; BOSUTINIB [WHO-DD]; Bosutinib (SKI-606)?; MLS006011212; SCHEMBL158390; BDBM4552; GTPL5710; orb1225150; orb1310890; orb3141310; Bosutinib Isomer 1, Free Base; Bosutinib, >=98% (HPLC); SCHEMBL29350234; SCHEMBL29428159; EX-A391; UBPYILGKFZZVDX-UHFFFAOYSA-N; GLXC-90178; HMS2043A22; HMS3244A03; HMS3244A04; HMS3244B03; HMS3651C03; HMS3672K11; HMS3743E09; HMS5079M03; K00615a; EBC-11336; HB1323; HY-10158R; NSC765694; NSC799367; SK 606; AKOS015902521; AC-2413; CCG-208129; CS-0118; DB06616; FB19002; NSC-765694; NSC-799367; PB30881; SDCCGSBI-0646926.P001; NCGC00241107-03; NCGC00241107-05; NCGC00241107-06; AS-11064; HY-10158; SMR002530350; NS00002757; S1014; SW220197-1; D03252; AB01565836_03; EN300-7565041; F794031; Q894611; SR-01000941572; SR-01000941572-1; BRD-K99964838-001-01-0; BRD-K99964838-001-06-9; BRD-K99964838-001-11-9; BRD-K99964838-001-12-7; Z2216885221; 3-QUINOLINECARBONITRILE, 4-((2,4-DICHLORO-5-METHOXYPHENYL)AMINO)-6-METHYL-1-PIPERAZINYL)PROPOXY)-; 4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)propoxy]quinoline-3-carbonitrileSinónimos
Productos que contienen Bosutinib
BOSUTINIB ZENTIVA 500 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB ZENTIVA 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB ZENTIVA 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB STADA 500 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB STADA 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB STADA 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB DR. REDDYS 500 COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB DR. REDDYS 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB DR. REDDYS 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB ZENTIVA 500 mg, comprimé pelliculéBOSUTINIB ZENTIVA 400 mg, comprimé pelliculéBOSUTINIB ZENTIVA 100 mg, comprimé pelliculé
Página 1 de 3
Empresas que venden Bosutinib
ML
MSN LaboratoriesIndiaRP
Reddy Pharma Iberia S.A.SpainLC
LEAP CHEM CO., LTD.Página 1 de 2